Melphalan, Etoposide, and Carboplatin Megatherapy with Autologous Stem Cell Transplantation in Children with Relapsing or Therapy-Resistant Extracranial Germ-Cell Tumors—A Retrospective Analysis

Melphalan, Etoposide, and Carboplatin Megatherapy with Autologous Stem Cell Transplantation in Children with Relapsing or Therapy-Resistant Extracranial Germ-Cell Tumors—A Retrospective Analysis

Pediatric germ cell tumors (GCTs) are a group of chemosensitive malignancies with a 90% curability rate. We report a series of children with relapsing or therapy-resistant GCT treated with melphalan–etoposide–carboplatin high-dose chemotherapy (HDCT) and autologous stem cell transplantation. This co...

Full description

Bibliographic Details
Main Authors:	Marek Ussowicz, Monika Mielcarek-Siedziuk, Jakub Musiał, Mateusz Stachowiak, Jadwiga Węcławek-Tompol, Dorota Sęga-Pondel, Jowita Frączkiewicz, Joanna Trelińska, Anna Raciborska
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Cancers
Subjects:	germ cell tumors high dose chemotherapy autologous stem cell transplantation
Online Access:	https://www.mdpi.com/2072-6694/12/12/3841

Similar Items

First hematopoietic stem cell transplantation in a child with late infantile Krabbe disease in Poland
by: Izabella Miśkiewicz-Migoń, et al.
Published: (2021-03-01)

The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder
by: Zofia Szmit, et al.
Published: (2022-09-01)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
by: Tricia Tay, et al.
Published: (2022-09-01)

Treatment Results of Extracranial Malignant Germ Cell Tumor with Regimens of Cisplatin, Vinblastine, Bleomycin or Carboplatin, Etoposide, and Bleomycin with Special Emphasis on the Sites of Vagina and Testis
by: Jen-Yin Hou, et al.
Published: (2015-10-01)

Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma
by: Lihong Zhang, et al.
Published: (2022-12-01)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
by: Rei Kamitani, et al.
Published: (2022-11-01)

Solid Cancers in the Premature and the Newborn: Report of Three National Referral Centers
by: Anna Raciborska, et al.
Published: (2016-08-01)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
by: Ping Zhou, et al.
Published: (2015-01-01)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
by: Ran Wu, et al.
Published: (2023-06-01)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma
by: Hyung-Chul Park, et al.
Published: (2012-08-01)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
by: Shiyu Jiang, et al.
Published: (2021-12-01)

Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient
by: Zhe Huang, et al.
Published: (2023-03-01)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
by: Nobuaki Mamesaya, et al.
Published: (2023-03-01)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
by: Soo Han Kim, et al.
Published: (2023-03-01)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
by: Ayako Shiono, et al.
Published: (2023-01-01)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
by: Masayuki Imaya, et al.
Published: (2022-05-01)

Long-Lasting Complete Remission of Small-Cell Carcinoma of the Pancreas with Carboplatin and Etoposide Complicated by Gallbladder Adenocarcinoma Diagnosed during Follow-Up
by: Konstantinos Tyriakidis, et al.
Published: (2021-03-01)

Small-cell neuroendocrine tumor of the bladder: Unexpected long-term survival with carboplatin-etoposide therapy in a patient with metastatic stage disease
by: Eduardo J García Rico, et al.
Published: (2023-01-01)

The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: “A Single-Center Experience”
by: Ali Eser, et al.
Published: (2021-05-01)

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
by: Reyes Bernabé, et al.
Published: (2024-01-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

Evaluating the Efficacy of Modified BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country
by: Mani Ramzi, et al.
Published: (2023-04-01)

Fludarabine–Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia
by: Małgorzata Salamonowicz-Bodzioch, et al.
Published: (2021-09-01)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
by: Yue-Ya Li, et al.
Published: (2015-06-01)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
by: Satoshi Wasamoto, et al.
Published: (2023-01-01)

Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?
by: Anase S. Asom, et al.
Published: (2022-02-01)

Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report
by: Yoshihiro Yamamoto, et al.
Published: (2022-05-01)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
by: Junko Johansson, et al.
Published: (2018-12-01)

Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial
by: Shun Lu, PhD, MD, et al.
Published: (2023-04-01)

Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
by: Paweł Marschollek, et al.
Published: (2022-11-01)

Safety and efficacy of posterior sub-Tenon’s carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds
by: Azza Mohamed Ahmed Said, et al.
Published: (2018-03-01)

Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience
by: Jérémy Baude, et al.
Published: (2024-01-01)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
by: Longfeng Zhang, et al.
Published: (2020-12-01)

MELPHALAN-INDUCED CYTOTOXICITY IN THE BONE MARROW OF RATS BY FLOW CYTOMETRY MEASUREMENTS
by: B I. Gerashchenko, et al.
Published: (2019-03-01)

Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells
by: Anastazja Poczta, et al.
Published: (2022-02-01)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
by: Ahmed Mahdy, et al.
Published: (2023-06-01)

FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.
by: Daniele Avenoso, et al.
Published: (2023-06-01)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021-03-01)

Effect of carboplatin injection on Bcl-2 protein expression and apoptosis induction in Raji cells
by: Peng Lin, et al.
Published: (2020-07-01)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
by: Thierry Berghmans, et al.
Published: (2017-09-01)